Stem Therapeutics Inc

Nonprofit profile at a glance

EIN
993860559
IRS 990-EZ coverage
2024–2025
Forms available
Form 990-EZ 2025
Location
San Diego, CA, USA
Phone
6192185912
Rating confidence
Limited
Sector
Cancer Research

Official website

Reported finances

Revenue
$0
Expenses
$462
Assets
$1,611
Liabilities
$0

Source: IRS Form 990-EZ. Selected filing: tax year 2025. Amounts in USD.

Leadership & pay

3 people listed

Executive titles in this filing

  • Anthony Conway (President / Director)

People named in this filing

  • Anthony Conway (President / Director)
  • Howard Federoff (Secretary / Chair of the Board)
  • David Schaffer (Treasurer / Director)

Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.

Source: IRS Form 990-EZ. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

The mission of Stem Therapeutics, Inc. is to develop universal stem cell-derived cellular therapies to treat diverse cancer patients with high unmet medical need to enable increased access to effective and safe cancer cell therapies close to home (the "Mission"). Stem Therapeutics is exempt under 501(c)(3) with public charity status of 170(b)(1)(A)(vi).

What it reported doing in 2025

None in 2025

Operating model

Revenue model
No positive adjusted resources. The filing reports no positive adjusted operating resources.
Distribution model
No current program activity. The filing reports no program spending for the current year.

The verdict

- The available evidence is not sufficient to produce an overall rating for this filing. This is not a warning sign.

Rating breakdown

  • Financial Efficiency: 0
  • Transparency & Controls: 82
  • Sustainability: 37
  • Growth: 0

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: Limited
  • Program expense ratio: 0%; rating input score 0

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 51st percentile among comparable filings
  • Major donor itemization: Limited

Sustainability

  • Operating margin: Limited
  • Total-asset coverage ratio: 3.49; rating input score 77; 77th percentile among comparable filings
  • Liabilities to assets ratio: 0; rating input score 66; 66th percentile among comparable filings
  • Officer compensation ratio: 0%; rating input score 56; 56th percentile among comparable filings

Growth

  • Program expense growth: Limited
  • Revenue growth: -200% per year; rating input score 0; 0th percentile among comparable filings
  • Asset growth: -25.1% per year; rating input score 0; 9th percentile among comparable filings

Details

  • Where the money goes: 0% of spending went to programs
  • Governance: Filed governance answers
  • Accomplishments: 1 filed program accomplishment
  • Leadership: top reported pay $0 · 3 people listed
  • Consistency: 9 of 9 current checks pass
  • Schedules: 1 filed schedules
  • Filing history: 2 filing years from 2024 to 2025
  • Contacts: How to reach this organization
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • High — Financial Efficiency: Program expense ratio scored 0/100.
  • High — Growth: Revenue growth scored 0/100.
  • High — Growth: Asset growth scored 0/100.
  • Review — Sustainability: Officer compensation ratio scored 56/100.